AEZS Aeterna Zentaris Inc

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. We are engaged in drug development activities and in the promotion of products for others. We are now conducting Phase 3 studies of two internally developed compounds. The focus of our business development efforts is the acquisition of or licenses to products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.

Company:

  Aeterna Zentaris Inc.  

Headquarters Address:

315 Sigma Drive Suite 302D Charleston, SC 29483  

Main Telephone:

843-900-3223  

Website:

www.aezsinc.com

 

Ticker:

AEZS(NASDAQ) AEZ(TSX)  

Type of Organization:

Public  

Industry:

Biotechnology  

Key Executives:

Chairman, President & CEO: David Dodd

SVP, Chief Administrative Officer & General Counsel: Philip Theodore

SVP & Chief Commercial Officer: Jude Dinges

 

Investor Relations

Contact:

Investor Relations

Email:

ir@aezsinc.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160226005007/en/